Skip to main content

Table 1 Demographics according to patient group; dialysis, renal transplant or autoimmune disease

From: SARS-COV-2 vaccine responses in renal patient populations

 

Dialysis

N = 260

Transplant

N = 209

Autoimmune

N = 223

Age (years) (median (range))

71 (20–95)

57 (23–78)

59 (19–88)

Sex (male) (Number (%))

149 (63)

108 (58)

90 (47)

Vaccine type (Number (%))

 - Pfizer

159 (61)

140 (67)

80 (36)

 - AstraZeneca

92 (36)

69 (33)

138 (62)

 - Unknown

9 (3)

0 (0)

5 (2)

Days between first and second vaccine doses (median (IQR))

 - Pfizer

77 (21–150)

77 (21–100)

76 (22–91)

 - AstraZeneca

77 (25–144)

77 (35–102)

77 (27–135)

PCR proven prior Covid-19 infection (Number(%))

20 (8)

14 (7)

5 (2)

Samples after 1st vaccine dose (Number(%))

234 (90)

180 (86)

152 (73)

 - Days after vaccination (median (IQR))

30 (18–88)

28 (14–75)

38 (21–118)

Samples after 2nd vaccine dose (Number(%))

236 (91)

185 (89)

201 (90)

 - Days after vaccination (median (IQR))

30 (12–119)

30 (11–94)

33 (19–75)

S antibody titre after first vaccine dose (IU)

7450 (2940–19,457)

556 (189–3936)

1388 (157–11,714)

 - Number(%) positive

189–234 (81)

61/180 (34)

69/152 (45)

S antibody titre after second vaccine dose (IU)

30,807 (26593–31,914)

4285 (295–26,230)

18,673 (1127–30,470)

 - Number(%) positive

227/236 (96)

104/185 (56)

140/201 (70)

  1. Dialysis patients were recruited from Cambridge (n = 217) and East and North Hertfordshire (n = 43). Data are reported at the time of most recent sampling. Antibody MFI titres greater than 1896 are considered positive